SGLT2 Inhibitor Use in Chronic Heart Failure with CKD Stage 3‑4

Guideline Recommendations

The 2021 Canadian Heart Failure Guidelines give a Class 1A (strong) recommendation for SGLT2‑inhibitors as foundational therapy in heart failure with reduced ejection fraction, explicitly including both dapagliflozin and empagliflozin regardless of diabetes status. [@1]
KDIGO 2022 and the ADA/KDIGO 2022 consensus statements issue a Class 1A (strong) recommendation for SGLT2‑inhibitors in adults with chronic kidney disease when eGFR ≥ 20 mL/min/1.73 m², covering CKD stage 3 (eGFR 30‑59) and stage 4 (eGFR 15‑29). [@2][@3]

In landmark trials, dapagliflozin (DAPA‑HF) and empagliflozin (EMPEROR‑Reduced) each reduced the composite of cardiovascular death or heart‑failure hospitalization with nearly identical hazard ratios (HR 0.74 [95 % CI 0.65‑0.85] vs HR 0.75 [95 % CI 0.65‑0.86]), demonstrating equivalent efficacy across the full range of kidney function down to eGFR 20 mL/min/1.73 m². [@1]
Both agents lower cardiovascular death, heart‑failure hospitalizations, and slow eGFR decline with comparable magnitude; empagliflozin slowed eGFR loss by 0.55 mL/min/1.73 m² yr⁻¹ versus 2.28 mL/min/1.73 m² yr⁻¹ in placebo, and reduced the composite kidney outcome (sustained eGFR decline, dialysis, or transplant) with HR 0.50. [@1]

Empagliflozin was studied in EMPEROR‑Reduced with enrollment allowed down to eGFR 20 mL/min/1.73 m²; subgroup analyses confirmed consistent cardiovascular and renal benefits at eGFR 20‑30. [@1]
Dapagliflozin was enrolled in DAPA‑HF at eGFR ≥ 25 mL/min/1.73 m², and DAPA‑CKD data support initiation at this threshold with continuation even if eGFR later falls below 25. [@1]
Both agents are appropriate for CKD stage 3 (eGFR 30‑59) and stage 4 (eGFR 15‑29) after confirming baseline eGFR. [@2][@3]
In CKD stage 4, empagliflozin has slightly stronger evidence for benefit at eGFR 20‑25, while dapagliflozin may be continued if eGFR drops below 25 after initiation. [@1]

Prescribe either empagliflozin 10 mg once daily or dapagliflozin 10 mg once daily for heart‑failure or CKD indications; lower doses are not recommended for these indications. [@1]
Do not use either agent for glucose‑lowering when eGFR < 45 mL/min/1.73 m², as glycemic efficacy is minimal, although cardiovascular and renal benefits persist. [@3]

Assess and correct volume status before starting therapy. [@3]
In patients at risk for hypovolemia (elderly, low blood pressure, or volume‑depleted), reduce loop or thiazide diuretic doses by 30‑50 %. [@3]
For patients with diabetes already at glycemic target, decrease insulin dose by ~20 % or reduce sulfonylurea dose to avoid hypoglycemia. [@3]

2‑4 weeks after initiation: re‑measure eGFR, volume status, blood pressure, and electrolytes. [@3]
An initial eGFR dip of 2‑5 mL/min/1.73 m² within the first 2‑4 weeks is expected (hemodynamic effect) and should not prompt discontinuation. [@3]
Every 3‑6 months (adjusted for CKD stage and clinical stability): repeat eGFR and electrolytes. [@3]
Continue the 10 mg daily dose even if eGFR falls below the original initiation threshold (below 25 for dapagliflozin, below 20 for empagliflozin); stop only when the patient requires chronic dialysis or kidney transplantation. [@3]

The early eGFR dip is not acute kidney injury and resolves within weeks; therapy should be maintained. [@3]
After the dip, eGFR trajectory stabilizes and the long‑term decline slope is attenuated compared with placebo. [@1]
Genital mycotic infections occur in ~6‑10 % of users; counseling on hygiene and use of topical antifungals allows continuation of therapy. [@3]
Sick‑day management: advise patients to hold the SGLT2‑inhibitor during acute illness with nausea, vomiting, diarrhea, or prolonged fasting to reduce risk of euglycemic diabetic ketoacidosis. [@3]
Blood‑pressure and volume monitoring is essential, especially in adults ≥ 65 years who have higher hypotension risk. [@3]
Combination with RAS blockers (ACE‑I, ARB, mineralocorticoid receptor antagonists) is safe; SGLT2‑inhibitors reduce hyperkalemia risk without causing hypokalemia, so they should not be withheld when patients are already on RAS blockade. [@3]

All facts are derived from peer‑reviewed guideline statements and major clinical trials, with citation identifiers provided for each bullet point.